Merck & Co's Gerberding Adds Dose Of Reality To COVID-19 Debate
Industry Must Not Over-Promise and Under-Deliver
Executive Summary
The US giant's chief patient officer and former head of the CDC, is proud of the "incredible collaboration" going on across the biopharmaceutical industry to tackle coronavirus but says "we have to be honest that we really don't understand this disease."
You may also be interested in...
Merck Cuts Pharma Revenue Guidance By $1.7bn Due To Pandemic
Overall, the pharma lowered its 2020 revenue guidance by $2.5bn at the midpoint, but also says it will save about $400m on SG&A expenses. Pandemic impacts expected mainly in Q2, normal resumption in Q4.
Merck’s Ervebo Becomes World’s First Approved Ebola Vaccine
Merck Sharp & Dohme will begin manufacturing licensed doses of Ervebo in Germany and will continue to send investigational vaccine doses to Democratic Republic of Congo.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.